Blast off! Mesoblast share price surging 60%

Mesoblast shares are skyrocketing today.

| More on:
Shot of a young scientist using a digital tablet while working in a lab.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Mesoblast Ltd (ASX: MSB) share price shot out of the gates on Tuesday, opening at 80 cents per share and rising to an intraday peak of 88.5 cents within the first two hours of trading.

The intraday high represents a 59.45% gain over the closing price of 55.5 cents last Thursday, prior to the market shutdown for the Easter long weekend.

At the time of writing, the Mesoblast share price has settled back to 87 cents per share.

What's the news from Mesoblast today?

The only news from the biotech company today is a non-price-sensitive announcement relating to a change in substantial holding.

That's for United States investor Gregory George and G to the Fourth Investments.

The notice advised a collective stake increase from 10.23% to 11.99% last Thursday.

There's no other news today.

However, Mesoblast did have a big announcement last week that sent its share price soaring.

Let's recap.

What's pushing the Mesoblast share price higher?

Mesoblast requested a pause in trading last Tuesday morning before releasing some big news.

The company announced that the US Food and Drug Administration (FDA) had informed it that after reviewing the clinical data from its Phase 3 study, there appeared to be sufficient evidence to support Mesoblast's submission for remestemcel-L to treat kids with steroid-refractory acute graft versus host disease (SR-aGVHD).

Remestemcel-L is being developed for inflammatory diseases in children and adults, including steroid-refractory acute graft versus host disease, and biologic-resistant inflammatory bowel disease.

CEO Silviu Itescu said the company would now refile its Biologics License Application (BLA). This will happen in the June quarter after the company addresses outstanding product characterisation matters.

Silviu said:

The responses and guidance from FDA are clear and provide us with a high level of confidence to refile our BLA for remestemcel-L in children with SR-aGVHD.

What is remestemcel-L?

This is the drug that Mesoblast has been trying to get approved for the past three-and-a-half years.

There was much excitement in mid-2020 while Mesoblast was awaiting the FDA's first decision on its flagship drug, also known as Ryoncil.

This can be seen in the Meosblast share price chart below.

Created with Highcharts 11.4.3Mesoblast PriceZoom1M3M6MYTD1Y5Y10YALLwww.fool.com.au

Remestemcel-L has FDA Fast Track designation, a process to facilitate the development and speedy
review of therapies for serious conditions that fill unmet medical needs.

It also has Priority Review designation, which is given to drugs that treat a serious condition and provide a significant improvement in safety or effectiveness over existing treatments.

Survival outcomes have not improved for 20 years for children or adults with the most severe forms of SR-aGVHD.

As you can see, the Mesoblast share price was trading above $5 per share back in those days.

The market was shocked when the FDA knocked back the application in October 2020.

Mesoblast worked with the FDA for two years to address the issues. It resubmitted its Biologics License Application (BLA) resubmission for remestemcel-L in the treatment of children in March 2023.

But the FDA knocked it back again in August. The Mesoblast share price spiralled down almost 60% after the FDA said it needed more data to support marketing approval for remestemcel-L for kids.

Mesoblast then sat down with the FDA in what is called a Type A meeting.

The FDA advised the company that the key remaining issue for pediatric approval was providing further evidence that the potency assay will assure the consistent efficacy of the commercial product.

Mesoblast later provided the FDA with new data from a second potency assay.

The company said:

The new data show that the RYONCIL product made with the current manufacturing process that
has undergone successful inspection by FDA, demonstrates greater potency than the earlier
generation product, providing context to its greater impact on survival.

Mesoblast has been waiting for the FDA to respond to the new data ever since.

Mesoblast share price snapshot

The Mesoblast share price is down 13.3% over the past 12 months.

However, in the year to date, it is up 174%.

Should you invest $1,000 in Appen Limited right now?

Before you buy Appen Limited shares, consider this:

Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now... and Appen Limited wasn't one of them.

The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

And right now, Scott thinks there are 5 stocks that may be better buys...

See The 5 Stocks *Returns as of 30 April 2025

Motley Fool contributor Bronwyn Allen has positions in Mesoblast. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

A man wakes up happy with a smile on his face and arms outstretched.
Healthcare Shares

ResMed shares jump 8% on strong Q3 update

It was yet another strong quarter from this high-quality company.

Read more »

A woman jumps for joy with a rocket drawn on the wall behind her.
Healthcare Shares

Guess which ASX All Ords stock is up 10% on big news

This high-flying stock just can't stop rising. What's going on?

Read more »

Teamwork, planning and meeting with doctors and laptop for medical, review and healthcare. Medicine, technology and internet with group of people for collaboration, diversity and support in hospital
Healthcare Shares

Telix shares rocket 15% on stellar Q1 sales update

Let's see how the company performed during the three months.

Read more »

Portrait, confidence and team of doctors in the hospital standing after a consultation or surgery. Success, healthcare and group of professional medical workers in collaboration at a medicare clinic.
Healthcare Shares

Macquarie's top 3 ASX stock picks in the healthcare sector

Top broker has revealed 3 healthcare stocks with upside. 

Read more »

Two lab workers fist pump each other.
Healthcare Shares

3 of the best ASX 200 healthcare shares to bring your portfolio to life

These shares could be just what the investment doctor ordered according to analysts.

Read more »

Medical workers examine an xray or scan in a hospital laboratory.
Share Gainers

Guess which ASX All Ords stock just rocketed 28% on a new commercial contract!

The ASX All Ords stock has grabbed plenty of investor interest on Tuesday.

Read more »

Five healthcare workers standing together and smiling.
Healthcare Shares

Is the CSL share price a buy? Here's a top broker's view

Is this stock a healthy opportunity? Let’s have a look.

Read more »

Man ecstatic after reading good news.
Healthcare Shares

Which ASX company has just secured FDA approval?

This stock just announced some big news.

Read more »